002262 Jiangsu Nhwa Pharmaceutical
- 24.50
- +0.13+0.53%
Jiangsu Nhwa Pharmaceutical News
Enhua Pharmaceutical (002262): Expectations of not collecting midazolam to increase
Enhua Pharmaceutical (002262): 1Q24 performance is in line with expectations, focus on the pace of new product release
Enhua Pharmaceutical (002262): Performance is in line with expectations, optimistic about the release of new products to drive long-term growth
Enhua Pharmaceutical (002262): Steady growth in performance, new products entering the release cycle
Enhua Pharmaceutical (002262): Excellent performance in the first year of 1Q24
Enhua Pharmaceutical (002262): The world has gone through a thousand sails, breaking the waves
Enhua Pharmaceutical (002262): Optimistic about new products to drive rapid growth in refined hemp
Pacific released a research report on April 9 stating that Enhua Pharmaceutical (002262.SZ) was given a purchase rating. The main reasons for the rating include: 1) the steady growth of the narcotics line and the rapid growth of the commercial sector; 2)
Enhua Pharmaceutical (002262): Performance meets expectations and strengthens product portfolio treatment plan
Enhua Pharmaceutical (002262): Steady growth in performance and continuous release of new narcotic products
Enhua Pharmaceutical (002262): Overall performance growth, R&D innovation continues to increase
Enhua Pharmaceutical (002262): Performance is in line with expectations, focusing on the release volume of large core products
Enhua Pharmaceutical (002262): The anesthesia line is growing steadily, and the release of new products can be expected
Enhua Pharmaceutical (002262) Company Information Update Report: Anesthetic products are growing steadily, and the incremental varieties “Hydroxericua” and TRV130 are expected to be further released
Enhua Pharmaceutical (002262): New narcotics products maintain rapid growth, innovative research and development accelerate
Enhua Pharmaceutical (002262): Fine hemp leading's revenue and profit increased rapidly in 2023
Enhua Pharmaceutical (002262) Company First Coverage Report: New Demand Helps Refine Hemp Market Expand and New Products Drive Company Performance Growth
Enhua Pharmaceutical (002262) In-depth Report: New Hemp Product Release Innovation Accelerates Driving
Enhua Pharmaceutical (002262): A leader in the hemp refining circuit, new opportunities for innovation and development
Enhua Pharmaceutical (002262) 2023 Third Quarter Report Review: Core Anesthetic Business Drives Growth, New Product Launch Imminent
Analysis
Price Target
No Data
